Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis.

Marnie Collins, Miriam Wilhelm, Rachel Conyers, Alan Herschtal, Jeremy Whelan, Stefan Bielack, Leo Kager, Thomas Kühne, Matthew Sydes, Hans Gelderblom, Stefano Ferrari, Piero Picci, Sigbjørn Smeland, Mikael Eriksson, Antonio Sérgio Petrilli, Archie Bleyer, David M. Thomas

Research output: Contribution to journalArticle

Abstract

The LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival. Suitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups. After accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated that a higher rate of chemotherapy-induced tumor necrosis was associated with longer survival (P <.001), as was female sex (P = .004) and the incidence of grade 3 or 4 mucositis (P = .03). Age group was not statistically significant in this landmark analysis (P = .12). Females reported higher rates of grade 3 or 4 thrombocytopenia relative to males (P <.001). Children reported the highest rates of grade 3 or 4 neutropenia (P <.001) and thrombocytopenia (P <.001). The achievement of good tumor necrosis was higher for females than for males (P = .002) and for children than for adults (P <.001). These results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes.

Original languageEnglish
Pages (from-to)2303-2312
Number of pages10
JournalJournal of Clinical Oncology
Volume31
Issue number18
DOIs
Publication statusPublished - Jun 20 2013

Fingerprint

Osteosarcoma
Meta-Analysis
Drug Therapy
Survival
Necrosis
Neoplasms
Mucositis
Neutropenia
PubMed
Thrombocytopenia
Registries
Young Adult
Histology
Multivariate Analysis
Survival Rate
Age Groups
Incidence
Population
Datasets

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma : findings from a meta-analysis. / Collins, Marnie; Wilhelm, Miriam; Conyers, Rachel; Herschtal, Alan; Whelan, Jeremy; Bielack, Stefan; Kager, Leo; Kühne, Thomas; Sydes, Matthew; Gelderblom, Hans; Ferrari, Stefano; Picci, Piero; Smeland, Sigbjørn; Eriksson, Mikael; Petrilli, Antonio Sérgio; Bleyer, Archie; Thomas, David M.

In: Journal of Clinical Oncology, Vol. 31, No. 18, 20.06.2013, p. 2303-2312.

Research output: Contribution to journalArticle

Collins, M, Wilhelm, M, Conyers, R, Herschtal, A, Whelan, J, Bielack, S, Kager, L, Kühne, T, Sydes, M, Gelderblom, H, Ferrari, S, Picci, P, Smeland, S, Eriksson, M, Petrilli, AS, Bleyer, A & Thomas, DM 2013, 'Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis.', Journal of Clinical Oncology, vol. 31, no. 18, pp. 2303-2312. https://doi.org/10.1200/JCO.2012.43.8598
Collins, Marnie ; Wilhelm, Miriam ; Conyers, Rachel ; Herschtal, Alan ; Whelan, Jeremy ; Bielack, Stefan ; Kager, Leo ; Kühne, Thomas ; Sydes, Matthew ; Gelderblom, Hans ; Ferrari, Stefano ; Picci, Piero ; Smeland, Sigbjørn ; Eriksson, Mikael ; Petrilli, Antonio Sérgio ; Bleyer, Archie ; Thomas, David M. / Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma : findings from a meta-analysis. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 18. pp. 2303-2312.
@article{f87726572f8a419f8a2c0cb6cf35c799,
title = "Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis.",
abstract = "The LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival. Suitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups. After accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated that a higher rate of chemotherapy-induced tumor necrosis was associated with longer survival (P <.001), as was female sex (P = .004) and the incidence of grade 3 or 4 mucositis (P = .03). Age group was not statistically significant in this landmark analysis (P = .12). Females reported higher rates of grade 3 or 4 thrombocytopenia relative to males (P <.001). Children reported the highest rates of grade 3 or 4 neutropenia (P <.001) and thrombocytopenia (P <.001). The achievement of good tumor necrosis was higher for females than for males (P = .002) and for children than for adults (P <.001). These results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes.",
author = "Marnie Collins and Miriam Wilhelm and Rachel Conyers and Alan Herschtal and Jeremy Whelan and Stefan Bielack and Leo Kager and Thomas K{\"u}hne and Matthew Sydes and Hans Gelderblom and Stefano Ferrari and Piero Picci and Sigbj{\o}rn Smeland and Mikael Eriksson and Petrilli, {Antonio S{\'e}rgio} and Archie Bleyer and Thomas, {David M.}",
year = "2013",
month = "6",
day = "20",
doi = "10.1200/JCO.2012.43.8598",
language = "English",
volume = "31",
pages = "2303--2312",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

TY - JOUR

T1 - Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma

T2 - findings from a meta-analysis.

AU - Collins, Marnie

AU - Wilhelm, Miriam

AU - Conyers, Rachel

AU - Herschtal, Alan

AU - Whelan, Jeremy

AU - Bielack, Stefan

AU - Kager, Leo

AU - Kühne, Thomas

AU - Sydes, Matthew

AU - Gelderblom, Hans

AU - Ferrari, Stefano

AU - Picci, Piero

AU - Smeland, Sigbjørn

AU - Eriksson, Mikael

AU - Petrilli, Antonio Sérgio

AU - Bleyer, Archie

AU - Thomas, David M.

PY - 2013/6/20

Y1 - 2013/6/20

N2 - The LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival. Suitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups. After accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated that a higher rate of chemotherapy-induced tumor necrosis was associated with longer survival (P <.001), as was female sex (P = .004) and the incidence of grade 3 or 4 mucositis (P = .03). Age group was not statistically significant in this landmark analysis (P = .12). Females reported higher rates of grade 3 or 4 thrombocytopenia relative to males (P <.001). Children reported the highest rates of grade 3 or 4 neutropenia (P <.001) and thrombocytopenia (P <.001). The achievement of good tumor necrosis was higher for females than for males (P = .002) and for children than for adults (P <.001). These results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes.

AB - The LIVESTRONG Young Adult Alliance has conducted a meta-analysis of individual patient data from prospective neoadjuvant chemotherapy osteosarcoma studies and registries to examine the relationships of sex, age, and toxicity on survival. Suitable data sets were identified by a survey of published data reported in PubMed. The final pooled data set comprised 4,838 patients from five international cooperative groups. After accounting for important variables known at study entry such as tumor location and histology, females experienced higher overall survival rates than males (P = .005) and children fared better than adolescents and adults (P = .002). Multivariate landmark analysis following surgery indicated that a higher rate of chemotherapy-induced tumor necrosis was associated with longer survival (P <.001), as was female sex (P = .004) and the incidence of grade 3 or 4 mucositis (P = .03). Age group was not statistically significant in this landmark analysis (P = .12). Females reported higher rates of grade 3 or 4 thrombocytopenia relative to males (P <.001). Children reported the highest rates of grade 3 or 4 neutropenia (P <.001) and thrombocytopenia (P <.001). The achievement of good tumor necrosis was higher for females than for males (P = .002) and for children than for adults (P <.001). These results suggest fundamental differences in the way chemotherapy is handled by females compared with males and by children compared with older populations. These differences may influence survival in a disease in which chemotherapy is critical to overall outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84882932037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882932037&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.43.8598

DO - 10.1200/JCO.2012.43.8598

M3 - Article

C2 - 23669227

AN - SCOPUS:84882932037

VL - 31

SP - 2303

EP - 2312

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18

ER -